British pharma firm claims small trial on a coronavirus treatment could signal ‘major breakthrough’ – CNBC

British pharmaceutical company Synairgen has claimed that its new respiratory coronavirus treatment has reduced the number of hospitalized Covid-19 patients needing intensive care in a clinical trial.
The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials, and patients that received the treatment “were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or vi…

Click here to view the original article.